MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
$149,049,000
EPS
$0.64
Unit: Dollar
Subscribe for Financial Insights
Page 1
Annual
123
Page 1
Income Statement
2025-12-31
Acquired in-process research and development
0
Research and development
349,000
General and administrative
5,693,000
Gain on sale of dismutase mimetics assets
3,500,000
Write-off of acquired intangible asset
0
Write-off of goodwill
0
Gain on litigation settlement
0
Loss from operations
-2,542,000
Interest income
248,000
Gain on extinguishment of debt
151,049,000
Change in fair value of warrant liability
-294,000
Foreign currency loss
0
Income (loss) before income tax benefit
149,049,000
Income tax benefit
0
Net income (loss)
149,049,000
Basic EPS
0.64
Diluted EPS
0.64
Basic Average Shares
98,503,430
Diluted Average Shares
98,503,430
Page 1
Unit: Dollar.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Gain on
extinguishment of debt
$151,049,000
Change in fair value of
warrant liability
-$294,000
Interest income
$248,000
Income (loss) before
income tax benefit
$149,049,000
Loss from operations
-$2,542,000
Gain on sale of
dismutase mimetics assets
$3,500,000
Net income (loss)
$149,049,000
General and
administrative
$5,693,000
Research and development
$349,000
Buy us a coffee
Galera Therapeutics, Inc. (GRTX)
Galera Therapeutics, Inc. (GRTX)